Login to Your Account

Cytos Plummets on Failed Hypertension Vaccine Study

By Donna Young

Wednesday, March 18, 2009
Shares of Cytos Biotechnology Ltd. plunged 32.8 percent on the Swiss stock exchange after the biotech said its vaccine candidate to treat hypertension, CYT006-AngQb, failed in a Phase IIa study to reduce patients' ambulatory blood pressures. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription